Sandbox/m02: Difference between revisions
< Sandbox
Gerald Chi- (talk | contribs) No edit summary |
Gerald Chi- (talk | contribs) No edit summary |
||
Line 1: | Line 1: | ||
{| style="border: 2px solid #696969;" align="center" | {| style="border: 2px solid #696969;" align="center" | ||
|+ <SMALL>''Classification, Dosage, and Side-Effects of Migraine Preventive Therapies.''<ref name="Silberstein-2012">{{Cite journal | last1 = Silberstein | first1 = SD. | last2 = Holland | first2 = S. | last3 = Freitag | first3 = F. | last4 = Dodick | first4 = DW. | last5 = Argoff | first5 = C. | last6 = Ashman | first6 = E. | title = Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. | journal = Neurology | volume = 78 | issue = 17 | pages = 1337-45 | month = Apr | year = 2012 | doi = 10.1212/WNL.0b013e3182535d20 | PMID = 22529202 }}</ref><ref name="Goadsby-2010">{{Cite journal | last1 = Goadsby | first1 = PJ. | last2 = Sprenger | first2 = T. | title = Current practice and future directions in the prevention and acute management of migraine. | journal = Lancet Neurol | volume = 9 | issue = 3 | pages = 285-98 | month = Mar | year = 2010 | doi = 10.1016/S1474-4422(10)70005-3 | PMID = 20170842 }}</ref></SMALL> | |+ <SMALL>''Classification, Dosage, and Side-Effects of Migraine Preventive Therapies.''<ref name="Silberstein-2012">{{Cite journal | last1 = Silberstein | first1 = SD. | last2 = Holland | first2 = S. | last3 = Freitag | first3 = F. | last4 = Dodick | first4 = DW. | last5 = Argoff | first5 = C. | last6 = Ashman | first6 = E. | title = Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. | journal = Neurology | volume = 78 | issue = 17 | pages = 1337-45 | month = Apr | year = 2012 | doi = 10.1212/WNL.0b013e3182535d20 | PMID = 22529202 }}</ref><ref name="Goadsby-2010">{{Cite journal | last1 = Goadsby | first1 = PJ. | last2 = Sprenger | first2 = T. | title = Current practice and future directions in the prevention and acute management of migraine. | journal = Lancet Neurol | volume = 9 | issue = 3 | pages = 285-98 | month = Mar | year = 2010 | doi = 10.1016/S1474-4422(10)70005-3 | PMID = 20170842 }}</ref></SMALL> | ||
| style="background: #A5B2D6; border: 0px solid #696969; padding: 0 5px; width: 10%" | ''' | | style="background: #A5B2D6; border: 0px solid #696969; padding: 0 5px; width: 10%" | '''Evidence''' | ||
| style="background: #A5B2D6; border: 0px solid #696969; padding: 0 5px; width: 15%" | '''Agent''' | | style="background: #A5B2D6; border: 0px solid #696969; padding: 0 5px; width: 15%" | '''Agent''' | ||
| style="background: #A5B2D6; border: 0px solid #696969; padding: 0 5px; width: 15%" | '''Dosage''' | | style="background: #A5B2D6; border: 0px solid #696969; padding: 0 5px; width: 15%" | '''Dosage''' |
Latest revision as of 04:08, 21 February 2014
Evidence | Agent | Dosage | Potential Side-Effects |
Level A Medications with established efficacy (>2 Class I trials) |
Antiepileptic Drugs | ||
▸ Divalproex sodium | 250 mg twice daily | Drowsiness, weight gain, tremor, hair loss, fetal abnormalities, hematological or liver abnormalities | |
▸ Sodium valproate | 400–600 mg twice daily | Drowsiness, weight gain, tremor, hair loss, fetal abnormalities, hematological or liver abnormalities | |
▸ Topiramate | 50–200 mg daily | Paresthesia, cognitive dysfunction, weight loss, care with a family history of glaucoma, nephrolithiasis | |
Beta Blockers | |||
▸ Metoprolol | 25–100 mg twice daily | Reduced energy, tiredness, postural symptoms; contraindicated in asthma | |
▸ Propranolol | 40–120 mg twice daily | Paresthesias, sleepiness, gastrointestinal intolerance | |
▸ Timolol | 10 mg twice daily | Reduced energy, tiredness, postural symptoms; contraindicated in asthma | |
Triptans (short-term prophylaxis of menstrually-related migraine) | |||
▸ Frovatriptan | 2.5 mg twice daily | Coronary artery vasospasm, transient myocardial ischemia, myocardial infarction, arrhythmia | |
Level B Medications are probably effective (1 Class I or 2 Class II studies) |
Antidepressants/SSRI/SSNRI/TCA | ||
▸ Amitriptyline | 25–75 mg every night | Nausea, vomiting, drowsiness, hypersomnolence, dry mouth, concentration difficulties | |
▸ Venlafaxine | 75–150 mg daily | Nausea, vomiting, drowsiness | |
Beta Blockers | |||
▸ Atenolol | 50 mg daily | Reduced energy, tiredness, postural symptoms; contraindicated in asthma | |
▸ Nadolol | 80–240 mg daily | Reduced energy, tiredness, postural symptoms; contraindicated in asthma | |
Triptans (short-term prophylaxis of menstrually-related migraine) | |||
▸ Naratriptan | 1 mg twice daily | Dizziness, chest pain, malaise | |
▸ Zolmitriptan | 2.5 mg twice daily | Asthenia, headache, dizziness, nausea | |
Level C Medications are possibly effective (1 Class II study) |
ACE Inhibitors | ||
▸ Lisinopril | 20 mg daily | Cough, dizziness | |
Angiotensin Receptor Blockers | |||
▸ Candesartan | 16 mg daily | Birth defects and fetal death | |
Alpha Agonists | |||
▸ Guanfacine | 1 mg daily | Dizziness, drowsiness, headache, constipation, diarrhea, loss of appetite, fatigue, nasal congestion | |
Antiepileptic Drugs | |||
▸ Carbamazepine | 200 mg daily | Drowsiness, motor coordination impairment, upset stomach | |
Beta Blockers | |||
▸ Nebivolol | 5 mg daily | Fatigue, clinical depression, bradycardia, impotence | |
Antihistamines | |||
▸ Cyproheptadine | 4 mg twice daily | Increased appetite, weight gain, abdominal discomfort, diarrhea, nausea, vomiting, xerostomia, depression, somnolence | |
Calcium Channel Blockers | |||
▸ Nicardipine | 20 mg twice daily | Headache, upset stomach, dizziness, fatigue, numbness, palpitations, constipation, heartburn |
References
- ↑ Silberstein, SD.; Holland, S.; Freitag, F.; Dodick, DW.; Argoff, C.; Ashman, E. (2012). "Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society". Neurology. 78 (17): 1337–45. doi:10.1212/WNL.0b013e3182535d20. PMID 22529202. Unknown parameter
|month=
ignored (help) - ↑ Goadsby, PJ.; Sprenger, T. (2010). "Current practice and future directions in the prevention and acute management of migraine". Lancet Neurol. 9 (3): 285–98. doi:10.1016/S1474-4422(10)70005-3. PMID 20170842. Unknown parameter
|month=
ignored (help)